Carrying the weight: Cancer caregivers and nutrition care
By Katrien Van Laere, SVP Research & Innovation, Chief Medical & Scientific Officer at Danone
A cancer diagnosis is a life-changing event for both the patient and their loved ones. In a matter of days people go from husband and wife, or parent and child, to patient and caregiver. In Europe 80% of long-term care is delivered by informal caregivers, with millions of Europeans looking after the 4.5 million people who are diagnosed with cancer in Europe every year.
New research conducted by Ipsos among informal cancer caregivers in Spain, Poland, France and Germany¹ showed that 93% of caregivers worry about the weight and muscle loss they notice in their loved ones.
As the people closest to a patient with cancer, caregivers are often the first ones to notice eating problems. In fact, almost all caregivers (98%) report observing at least one eating problem like appetite loss or nausea in their loved ones. Such problems are caused by the disease itself and its treatment, increasing the risk of weight and muscle loss and becoming malnourished.
Caregivers are right to worry about the weight loss they notice in their loved ones. It is a visible sign of cancer-related malnutrition which affects up to 80% of patients with cancer². Malnutrition negatively impacts their cancer treatment and recovery outcomes, resulting in more complications, a higher risk of infections, longer hospital stays, and increased mortality.
Beyond its grave impact on the lives of patients and caregivers, the systemic burden of malnutrition in cancer is immense, adding up to an estimated extra €120 billion in cancer treatment costs across Europe³.
Despite its prevalence and associated adverse effects, cancer-related malnutrition remains widely underrecognized. Systematic screening for malnutrition is not always integrated in cancer care and solutions like medical nutrition are not known to patients and caregivers, nor are they an integral part of cancer policies or care pathways.
At Danone we are convinced medical nutrition is fundamental in addressing cancer-related malnutrition, an issue that affects the majority of patients with cancer. Prescribed by a healthcare professional, medical nutrition is clinically proven to contribute to maintenance of weight and muscle mass compared to no intervention⁴, fewer post-op complications⁵, improved tolerance to treatment⁶, shorter length of hospital stay⁷, and higher patient quality of life⁸. As such it can also help to relieve some of the fundamental concerns tabled by caregivers in the recent research.
Yet at present, only 1 out of 3 patients with cancer who need medical nutrition actually receive it⁹. This in part is due to a lack of awareness of the role of nutrition in cancer care, but also because weight loss is often seen as inevitable when going through the disease.
All patients and caregivers deserve the best chance in their fight against cancer. Solutions that address malnutrition can support them in this fight which is why everyone who needs medical nutrition should have access to it. Holistic approaches in cancer care as part of which patients are systematically screened for malnutrition and provided medical nutrition, are more necessary than ever and Danone calls for these to become an integral part of Europe's Beating Cancer Plan, National Cancer Control Plans as well as cancer care pathways and protocols everywhere.
_____________________________
¹ Ipsos European Informal Caregiver Experience survey with 1000 caregivers from France, Germany, Poland and Spain, data on file, 2024.
² Arends J, et al. Crit Rev Oncol Hematol. 2023:185:103965
³ Caccialanza R, et al. Supportive Care in Cancer. 2022;30:9667–9679
⁴ Grupinska J, et al. Nutrients. 2021;13(10):3549; Cereda E, et al. Nutritional Radiother Oncol. 2018;126(1):81-88; Tan S, et al. Clin Nutr. 2021;40(1):47-53.
⁵ Maňásek et al. 2016 Klin Onkol, 29(5):351-357
⁶ Meng Q, et al. Clin Nutr. 2021;40(1):40-46 ; Cereda et al. 2018 Radiother Oncol; 126(1):81-88
⁷ Adiamah et al. 2019 Annals Surgery, 270(2):247-256
⁸ Cereda E, et al. Nutritional Radiother Oncol. 2018;126(1):81-88; Tan S, et al. Clin Nutr. 2021;40(1):47-53.; Baldwin C, et al. J Natl Cancer Inst. 2012;104(5):371-85
⁹ Bavelaar et al, Clin Nutr. 2008 Jun;27(3):431-8; Meijers JM, et al. Nutrition. 2009 May;25(5):512-9; Planas et al. 2015 Support Care Cancer, 24, 429-435
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
4 days ago
- Euronews
Carrying the weight: Cancer caregivers and nutrition care
By Katrien Van Laere, SVP Research & Innovation, Chief Medical & Scientific Officer at Danone A cancer diagnosis is a life-changing event for both the patient and their loved ones. In a matter of days people go from husband and wife, or parent and child, to patient and caregiver. In Europe 80% of long-term care is delivered by informal caregivers, with millions of Europeans looking after the 4.5 million people who are diagnosed with cancer in Europe every year. New research conducted by Ipsos among informal cancer caregivers in Spain, Poland, France and Germany¹ showed that 93% of caregivers worry about the weight and muscle loss they notice in their loved ones. As the people closest to a patient with cancer, caregivers are often the first ones to notice eating problems. In fact, almost all caregivers (98%) report observing at least one eating problem like appetite loss or nausea in their loved ones. Such problems are caused by the disease itself and its treatment, increasing the risk of weight and muscle loss and becoming malnourished. Caregivers are right to worry about the weight loss they notice in their loved ones. It is a visible sign of cancer-related malnutrition which affects up to 80% of patients with cancer². Malnutrition negatively impacts their cancer treatment and recovery outcomes, resulting in more complications, a higher risk of infections, longer hospital stays, and increased mortality. Beyond its grave impact on the lives of patients and caregivers, the systemic burden of malnutrition in cancer is immense, adding up to an estimated extra €120 billion in cancer treatment costs across Europe³. Despite its prevalence and associated adverse effects, cancer-related malnutrition remains widely underrecognized. Systematic screening for malnutrition is not always integrated in cancer care and solutions like medical nutrition are not known to patients and caregivers, nor are they an integral part of cancer policies or care pathways. At Danone we are convinced medical nutrition is fundamental in addressing cancer-related malnutrition, an issue that affects the majority of patients with cancer. Prescribed by a healthcare professional, medical nutrition is clinically proven to contribute to maintenance of weight and muscle mass compared to no intervention⁴, fewer post-op complications⁵, improved tolerance to treatment⁶, shorter length of hospital stay⁷, and higher patient quality of life⁸. As such it can also help to relieve some of the fundamental concerns tabled by caregivers in the recent research. Yet at present, only 1 out of 3 patients with cancer who need medical nutrition actually receive it⁹. This in part is due to a lack of awareness of the role of nutrition in cancer care, but also because weight loss is often seen as inevitable when going through the disease. All patients and caregivers deserve the best chance in their fight against cancer. Solutions that address malnutrition can support them in this fight which is why everyone who needs medical nutrition should have access to it. Holistic approaches in cancer care as part of which patients are systematically screened for malnutrition and provided medical nutrition, are more necessary than ever and Danone calls for these to become an integral part of Europe's Beating Cancer Plan, National Cancer Control Plans as well as cancer care pathways and protocols everywhere. _____________________________ ¹ Ipsos European Informal Caregiver Experience survey with 1000 caregivers from France, Germany, Poland and Spain, data on file, 2024. ² Arends J, et al. Crit Rev Oncol Hematol. 2023:185:103965 ³ Caccialanza R, et al. Supportive Care in Cancer. 2022;30:9667–9679 ⁴ Grupinska J, et al. Nutrients. 2021;13(10):3549; Cereda E, et al. Nutritional Radiother Oncol. 2018;126(1):81-88; Tan S, et al. Clin Nutr. 2021;40(1):47-53. ⁵ Maňásek et al. 2016 Klin Onkol, 29(5):351-357 ⁶ Meng Q, et al. Clin Nutr. 2021;40(1):40-46 ; Cereda et al. 2018 Radiother Oncol; 126(1):81-88 ⁷ Adiamah et al. 2019 Annals Surgery, 270(2):247-256 ⁸ Cereda E, et al. Nutritional Radiother Oncol. 2018;126(1):81-88; Tan S, et al. Clin Nutr. 2021;40(1):47-53.; Baldwin C, et al. J Natl Cancer Inst. 2012;104(5):371-85 ⁹ Bavelaar et al, Clin Nutr. 2008 Jun;27(3):431-8; Meijers JM, et al. Nutrition. 2009 May;25(5):512-9; Planas et al. 2015 Support Care Cancer, 24, 429-435
Euronews
22-05-2025
- Euronews
Why the UK is offering vaccines for gonorrhoea – and the EU isn't
In a world first, the United Kingdom is rolling out a vaccine to prevent gonorrhoea – but it is not likely to reach patients in mainland Europe anytime soon. The jab will be offered through the UK's National Health Service to people in England at high risk of contracting gonorrhoea, after a vaccine advisory committee concluded in 2023 that it could help reduce the country's surge of sexually transmitted infections (STIs). In studies, the vaccine was between 32.7 per cent and 42 per cent effective against gonorrhoea, the advisory group found. That means the jab could help reduce, but not completely eliminate, the risk of infection. The vaccine, known as 4CMenB and sold by GSK as Bexsero, was not originally created with gonorrhoea in mind. It's been authorised for more than a decade in both the UK and the European Union to prevent meningococcal disease, which causes meningitis and bloodstream infections. The UK has recommended that babies receive the vaccine since 2015, with Ireland, Italy, Portugal, France, and Germany later following suit. Uptake has been spotty elsewhere in the EU. The bacteria that cause meningococcal disease and gonorrhoea are closely genetically related. Real-world data from New Zealand and elsewhere indicate that the 4CMenB jab could be particularly effective against gonorrhoea, though a randomised trial in France concluded that it was not effective. The vaccine hasn't been approved to prevent gonorrhoea in the UK, meaning the NHS programme will offer it for off-label use. Beginning in August, gay and bisexual men who have a recent STI or history of multiple sexual partners will be eligible for immunisation, in the hopes of slowing the bacteria's spread. England saw 85,000 new gonorrhoea cases in 2023, the highest level since records began in 1918, the NHS said. The vaccine 'has the potential to help us to turn that around,' Matt Phillips, president of the British Association for Sexual Health and HIV, said in a statement. But other Europeans won't have access to the jab. The EU's scientific advisory group is not considering whether it should be authorised to prevent gonorrhoea, and a GSK spokesperson told Euronews Health that the drugmaker is not in talks with regulators to change that. Meanwhile, health authorities in France and Italy told Euronews Health that the jab is not on their agendas, and a German representative pointed to a review that found mixed results on the efficacy of the vaccine to prevent gonorrhoea. The Norwegian public health agency noted that the vaccine offers 'some protection' against gonorrhoea, but it stopped short of endorsing the jab. Gonorrhoea is one of the most common STIs, with nearly 97,000 confirmed cases in 28 European countries in 2023 – up 31 per cent from the year before, according to the European Centre for Disease Prevention and Control (ECDC). Cases have been rising among all age groups and among both women and men, with men who have sex with men accounting for 58 per cent of cases in 2023. Gonorrhoea can cause burning during urination, discharge from the genitals, and pain in the lower abdomen or testicles. It can lead to serious health issues if left untreated, such as pelvic inflammatory disease in women. Symptoms typically appear two weeks after infection, but many people don't have symptoms and can unknowingly spread gonorrhoea to their sexual partners. Gonorrhoea can be treated with antibiotics, though the surge of cases in recent years raises the risk that people will be infected with drug-resistant strains that are harder to treat. That's one problem the UK is hoping to address with the new vaccination programme, according to Dr Sema Mandal, deputy director of the UK Health Security Agency. 'This vaccination programme is a hugely welcome intervention at a time when we're seeing very concerning levels of gonorrhoea, including antibiotic resistant gonorrhoea,' Mandal said in a statement. A startup in France is leveraging artificial intelligence-backed physics principles in the hope of speeding up the process of making new drugs. Currently, developing a new medicine takes a company 10 to 15 years on average, with research conducted in a lab environment – and a lot of trial and error before they enter multiple stages of human clinical trials. It's also an expensive process, with only 10 to 20 per cent of experimental drugs in clinical trials eventually being approved. Those are problems the France-based Aqemia is trying to solve. The company, founded in 2019 by quantum physics researcher Maximilien Levesque and Emmanuelle Martiano, a former consultant for Boston Consulting Group, aims to use artificial intelligence (AI) to more efficiently create new molecules for drugs that treat cancers of the head, neck, and chest, such as lung cancer. It wants to "develop medicine faster in a frugal and accurate way," Dr Véronique Birault, Aqemia's vice president of translational sciences, told Euronews Health at the company's new London hub, which opened in January. To do so, Aqemia is using both AI and fundamental physics, which Levesque worked on during his academic career. Many healthcare companies are turning to AI tools in the drug discovery process, but they usually need to be trained on a large corpus of data – which doesn't always exist for these new molecules, according to Levesque. For example, "there aren't billions and billions and billions of drugs for chest cancer" that the AI models could be trained on, Levesque told Euronews Health. Instead of feeding their AI model with raw data, the team feeds it the rules of physics at the level of atoms and molecules tied to specific diseases. That includes a mathematical equation that Levesque solved, which the team says can be leveraged to identify "better molecules" that are "more effective". "It's as if, rather than swallowing lists of numbers, you had a maths teacher teaching you how to count," Levesque added. Aqemia isn't the only company betting on AI for drug discovery. Worldwide, 10 major pharmaceutical companies have signed more than 130 deals for AI collaborations since 2021. AI models can quickly analyse datasets to uncover patterns, helping scientists predict which molecules are linked to certain diseases and identifying promising drug candidates for new drugs or treatments. To some extent, they can also help forecast how people will respond to new drugs. For example, Google's AlphaFold system – which won the Nobel Prize in Chemistry in 2024 – uses AI to predict a protein's 3D structure and how it will interact with other molecules. Aqemia has signed partnerships with pharmaceutical giants like Sanofi, Servier, and Johnson & Johnson to research potential new drugs, Levesque said. But he cautioned that even as the company works on speeding up the molecular development phase, it can't influence the clinical development stage, which takes an average of nine years. Some research indicates that may also be changing. A handful of AI-discovered molecules are in early stage trials, with cancer-related drugs making up about half of those in phase one and phase two studies. Aqemia could be part of the next wave. "Our internal programmes are progressing and we already have programmes showing efficacy and non-toxicity on mice with cancer," he said. The company hopes to launch clinical trials testing new molecules in late 2026 or early 2027.
France 24
14-05-2025
- France 24
'No more empty statements:' Iran ex-detainees press Sweden over death row academic
Ahmadreza Djalali, an academic who was sentenced to death in 2017 on espionage charges he denies, suffered a heart attack in Tehran's Evin prison, his wife said Friday. Djalali, 53, is among a number of Europeans held by Iran in what some countries including France call a deliberate hostage-taking strategy to extract concessions from the West at a time of tension over Tehran's nuclear programme. Djalali's condition, "worsened by years of medical neglect and psychological torment, is now dire," said the 21 former detainees including British-Iranian Nazanin Zaghari-Ratcliffe, Australian Kylie Moore-Gilbert and US-Iranian Siamak Namazi, who were freed only after years-long ordeals in prison. "While the Islamic Republic and its heinous practice of hostage diplomacy is the clear culprit here, we are deeply troubled by your government's failure to use the means at its disposal to rescue Dr Djalali," they said in the letter addressed to Swedish Prime Minister Ulf Kristersson via Stockholm's embassy in Washington. "No more empty statements. Sweden must act with the same urgency and resolve it has shown in securing the freedom of other citizens," they added in the letter seen by AFP. Djalali was granted Swedish nationality while in jail. 'A path home' The letter said Iranian Foreign Minister Abbas Araghchi had offered a possible way forward in a recent social media post that it said "implicitly linked" the case to Iran's inability to access treatment for epidermolysis bullosa (EB), a disease that affects hundreds of Iranian children and can be fatal without proper care. "The specialised wound dressings required to treat EB, produced by a Swedish company, have long been blocked due to over-compliance with sanctions," the letter said. In a post on X last week that lamented a "regrettable shift" in bilateral relations, Araghchi said "Sweden ceased non-sanctionable exports of medicines, including specialised and unique gear for children afflicted with EB". In June 2024, Tehran freed two Swedes held in Iran in exchange for Hamid Noury, a former Iranian prisons official serving a life sentence in Sweden. To the disappointment of his family, Djalali was not included in the swap. In the letter, the ex-detainees told Kristersson: "A path to bring Dr Djalali home -- alive, not in a coffin -- appears within reach. "If Sweden fails to pursue it seriously and this Swedish citizen dies in captivity, history will record that your government had more than one chance to save him -- but chose not to. That responsibility will rest squarely with you." © 2025 AFP
